Form 8-K for MULTICELL TECHNOLOGIES, INC.
[RWS, This filing seems to clearly show how much MCET is paying Columbia University for the research, that I would guess has more than just altruistic potential to help people by protecting against RGC death...I wonder what the market potential is for this? And if there are any other companies that are focused on this type of research for a comparison.
NOTE: As you probably know, in the past I have tried to reply in a constructive way to usernames "Tradeinride" and "EACarl", as I am always open to hearing both sides on what a company is doing right, in addition to what they are doing wrong, or could be doing better, but I find the person or persons who post under those usernames to be consistently one-sided and unconstructive in their opinions. Therefore, I have both of those usernames on IGNORE. If they choose not to invest in MCET or keep trying to get it for less money, then that is their choice, but take heart in knowing that you are not the only one on SI who feels that MCET has the potential to be a very lucrative investment; and in more than one area, IMHO! Take Care, Shawn PS: There are alot of companies and industries that I follow, but of the small ones that also has an active thread on SI, SRAM currently seems to be a very good buy, in my humble opinion. Any companies that you would recommend? ] --------------------------------------------------------------------------------
1-Dec-2005
Entry into Material Agreement, Other Events, Financial Statements an
Item 1.01. Entry into a Material Definitive Agreement.
On December 1, 2005, MultiCell Technologies, Inc. (the Company) entered into Research Agreement (the Agreement) with The Trustees of Columbia University (Columbia). Among other things, the Agreement provides for the investigation of a novel anti-apoptosis compound. The research project is designed to determine whether the compound can protect against Retinal Ganglion cell (RGC) death in acute and chronic in vivo models of optic neuropathy. The research will be conducted in a Columbia laboratory under the direction of Dr. James Tsai, Associate Professor of Ophthalmology. The Company will provide financial support for the research during the two year term of the Agreement in an aggregate amount of at least approximately $310,000, subject to certain adjustments. The Company will also pay Columbia an additional $50,000 in consideration of Columbia's grant to the Company of an option to enter into an exclusive world-wide license for any invention resulting from the research, subject to certain conditions. Subject to the Company's option, Columbia will own any invention or research information that results from the research.
The Company expects to file the Agreement with its next annual report on Form 10-KSB. In addition, the Company intends to apply for confidential treatment of certain terms of the Agreement.
Item 8.01. Other Events.
On December 1, 2005, the Company issued a press release announcing the execution of the Agreement. A copy of this press release is attached hereto as Exhibit
99.1. This summary is qualified in its entirety by reference to Exhibit 99.1 to this current report.
This information and the exhibits hereto are being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
99.1 Press Release dated December 1, 2005.
biz.yahoo.com |
